THE EVIDENCE TO FIGHT ON with ONIVYDE®

The first and only FDA-approved treatment, in combination with 5-FU/LV, for metastatic pancreatic cancer after gemcitabine-based therapy, proven to extend overall survival1 (Median OS: 6.1 months vs 4.2 months for 5-FU/LV alone)

arrow down
 
check icon

FDA-APPROVED FOR METASTATIC PANCREATIC CANCER AFTER GEMCITABINE, IN COMBINATION WITH 5‑FU/LV1

66%* of patients in the phase 3 NAPOLI-1 trial received ONIVYDE® + 5-FU/LV in first- and second-line metastatic pancreatic cancer after gemcitabine-based therapy1,2

VIEW DETAILS
check icon

CATEGORY 1 NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CHEMOTHERAPY RECOMMENDATION3†

Irinotecan liposome injection (ONIVYDE®) + 5-FU/LV is the only Category 1 NCCN chemotherapy recommendation in post-gemcitabine metastatic pancreatic cancer3

Liposomal irinotecan + 5-FU/LV is the only Category 1 National Comprehensive Cancer Network® (NCCN®) chemotherapy recommendation for patients with post-gemcitabine metastatic pancreatic cancer with good performance status and disease progression. Good performance status is defined as ECOG 0-1 with good biliary drainage and adequate nutritional intake.3 See the NCCN Guidelines for Pancreatic Adenocarcinoma for a complete list of recommended treatment options. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

REVIEW NOW

5-FU=fluorouracil; ECOG=Eastern Cooperative Oncology Group; LV=leucovorin.

*Previous lines of metastatic therapy: 0=13%;1=53%2

liposome

LIPOSOMAL ENCAPSULATION1

ONIVYDE® is a liposomal encapsulation that allows for prolonged circulation1

LEARN MORE
safety icon

SAFETY PROFILE STUDIED IN A LARGE PHASE 3 TRIAL1

The safety profile of ONIVYDE® + 5-FU/LV was studied in NAPOLI-1, the largest phase 3 trial in patients with metastatic pancreatic cancer with disease progression after gemcitabine-based therapy1,4

SEE CLINICAL RESULTS
ipsen care icon

IPSEN CARES®

Tap into helpful resources on coverage, access, and reimbursement for patients and caregivers

GET HELP